Novartis Pitching New Product: A Fund For Tropical Disease Research

Novartis executive Paul Herrling has been on a whirlwind promotional tour the past few weeks. He's met with government leaders in China, Germany and the Netherlands, and academicians at Yale University, Columbia University and the New York Academy of Sciences. His goal: convincing them to support a new way to fund research on medicines for tuberculosis, dengue fever and other neglected tropical diseases